Program is on track for clinical trial start in H2 2019
TORONTO and CAMBRIDGE, MA, June 12, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the initiation of producer cell line development for PMN310, its lead therapeutic antibody candidate for treatment of Alzheimer's disease (AD). Selexis, SA will carry out this critical first step in the manufacturing of antibody therapeutics using the proprietary Selexis SUREtechnology Platform™.
ProMIS' lead antibody product candidate, PMN310, is a humanized antibody that binds with high affinity and selectivity for the toxic oligomers of amyloid beta (Aβ), a recognized root cause of AD. PMN310 is anticipated to enter phase I clinical trials in the second half of 2019.
"We recently completed successful affinity maturation of PMN310, which in addition to its unique and highly selective binding profile offers increased opportunity for best in class therapy for Alzheimer's disease," said Dr. Elliot Goldstein, ProMIS President and CEO. "We are now initiating the manufacturing process with Selexis' proprietary, high-performance technology platform for cell line development based on its proven track record for rapid and stable production of antibody therapeutics such as PMN310."
Selexis' proprietary and high performance SUREtechnology Platform facilitates the rapid, stable and cost-effective production of virtually any recombinant protein including those that are difficult to express in other systems.
"It is rewarding for us to leverage the fast speed/timelines and superior performance of the Selexis platform to rapidly and predictably advance PMN310 into the clinic with the goal of supporting ProMIS Neurosciences as they seek to bring a much needed treatment option to patients with Alzheimer's disease," said Yemi Onakunle, PhD, Selexis vice president, business development and licensing. "We believe our best-in-class technology can help propel forward this best-in-class therapeutic candidate."
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis' SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, more than 100 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. This news release contains certain "forward-looking statements" within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates", believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.
SOURCE ProMIS Neurosciences Inc.
For further information: Media inquiries for ProMIS: David Schull, RussoPartners/LLC, [email protected], Tel. 858 717-2310; Investor Relations inquiries for ProMIS: Alpine Equity Advisors, Nicholas Rigopulos, President, [email protected], Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, [email protected]; Media Inquiries for Selexis: Mike Beyer, Sam Brown Inc., [email protected], Tel. 312-961-2502; Company Inquiries for Selexis: Robert Meister, Head, Corporate Communications, [email protected], Tel. 602-953-1716
ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of...